Abstract
The present study mucoadhesive buccal tablets of Olmesartan can be used to bypass the extensive hepatic first-pass metabolism and improve the bioavailability. The mucoadhesive Buccal tablets of Olmesartan are a drug of choice in the treatment of high blood pressure, heart failure, and diabetic kidneys. The FTIR results revealed that there was no interaction between drugs and other excipients. All the post-compression parameter was within acceptable limits. The in vitro drug release was in the range of 85.35% to 99.65% after 8 hrs the very best regression integrity (r) the best fit role model for F1 to F8 used to be zero-order and for F9 it was Higuchi matrix.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Future Journal of Pharmaceuticals and Health Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
